Evaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial

References

• Zeidan AZ, Al Sayed B, Bargaoui N, et al. A review of the efficacy, safety, and cost‐effectiveness of COX‐2 inhibitors for Africa and the Middle East region. Pain Pract. 2013;13(4):316–331. doi:10.1111/j.1533-2500.2012.00591.x
   Web of Science ®Google Scholar
• Whittle B. COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors. Gut. 2000;47(3):320–325. doi:10.1136/gut.47.3.320
   Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–1080. doi:10.1056/NEJMoa050405
   PubMed Web of Science ®Google Scholar
• Bhala N, Emberson J, Merhi A, et al.; Coxib and traditional NSAID Trialists’(CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779.
   PubMed Web of Science ®Google Scholar
• Walker C, Biasucci LM. Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. Postgrad Med. 2018;130(1):55–71. doi:10.1080/00325481.2018.1412799
   PubMed Web of Science ®Google Scholar
• Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–2529. doi:10.1056/NEJMoa1611593
   PubMed Web of Science ®Google Scholar
• Solomon DH, Husni ME, Wolski KE, et al. Differences in safety of nonsteroidal antiinflammatory drugs in patients with osteoarthritis and patients with rheumatoid arthritis: a Randomized Clinical Trial. Arthritis Rheumatol. 2018;70(4):537–546. doi:10.1002/art.40400
   PubMed Web of Science ®Google Scholar
• Hammoumraoui N, Kherraf SA, Mould-Quevedo J, Ismail TA. The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors for treating osteoarthritis in Algeria. J Health Econ Outcomes Res. 2013;1(2):184–199. doi:10.36469/9865
   Google Scholar
• Nasef SA, Shaaban AA, Mould-Quevedo J, Ismail TA. The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia. Health Econ Rev. 2015;5(1):13. doi:10.1186/s13561-015-0053-7
   Web of Science ®Google Scholar
• Chen Y, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess (Rockv). 2008;12(11):1–278. doi:10.3310/hta12110
   PubMed Web of Science ®Google Scholar
• Brereton N, Winn B, Akehurst R. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial. J Med Econ. 2012;15(3):465–472. doi:10.3111/13696998.2012.659778
   Google Scholar
• Brereton N, Pennington B, Ekelund M, Akehurst R. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model. J Med Econ. 2014;17(9):677–684. doi:10.3111/13696998.2014.933111
   Google Scholar
• National Collaborating Centre for Chronic Conditions. Appendix D, Osteoarthritis: National Clinical Guidelines for Care and Management in Adults. London: Royal College of Physicians; 2008:2014.
   Google Scholar
• Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community‐based settings. Pain Pract. 2012;12(7):550–560. doi:10.1111/j.1533-2500.2012.00532.x
   PubMed Web of Science ®Google Scholar
• Federal Competitiveness and Statistics Authority. Consumer Price Index (CPI) Report, UAE; April, 2020. Available from: www.fcsa.gov.ae. Accessed March 25, 2021.
   Google Scholar
• Latimer N, Lord J, Grant RL, O’Mahony R, Dickson J, Conaghan PG. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ. 2009;339:b2538. doi:10.1136/bmj.b2538
   Web of Science ®Google Scholar
• Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective. Appl Health Econ Health Policy. 2013;11(3):219–236. doi:10.1007/s40258-013-0031-3
   Google Scholar
• McDougall JA, Furnback WE, Wang BC, Mahlich J. Understanding the global measurement of willingness to pay in health. J Mark Access Health Policy. 2020;8(1):1717030. doi:10.1080/20016689.2020.1717030
   PubMedGoogle Scholar
• Adam T. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Vol. 1. World Health Organization; 2003.
   Google Scholar
• Ram P. Management of Healthcare in the Gulf Cooperation Council (GCC) countries with special reference to Saudi Arabia. Int J Acad Res Bus Soc Sci. 2014;4(12):24. doi:10.6007/IJARBSS/v4-i12/1326
   Google Scholar
• Khoja T, Rawaf S, Qidwai W, Rawaf D, Nanji K, Hamad A. Health care in Gulf Cooperation Council countries: a review of challenges and opportunities. Cureus. 2017;9(8). doi:10.7759/cureus.1586
   Web of Science ®Google Scholar
• Alharbi MF. An analysis of the Saudi health-care system’s readiness to change in the context of the Saudi National Health-care Plan in Vision 2030. Int J Health Sci. 2018;12(3):83.
   Google Scholar
• Rahman R, Alsharqi OZ. What drove the health system reforms in the Kingdom of Saudi Arabia? An analysis. Int J Health Plann Manage. 2019;34(1):100–110. doi:10.1002/hpm.2584
   PubMed Web of Science ®Google Scholar
• Koornneef E, Robben P, Blair I. Progress and outcomes of health systems reform in the United Arab Emirates: a systematic review. BMC Health Serv Res. 2017;17(1):672. doi:10.1186/s12913-017-2597-1
   PubMed Web of Science ®Google Scholar
• El-Hassan O, Sharif A, Al MR, Blair I. Tracking the implementation of electronic medical records in Dubai, United Arab Emirates, using an adoption benchmarking tool. Stud Health Technol Inform. 2017;245:64–68.
   Google Scholar
• Solomon DH, Husni ME, Libby PA, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION Trial. Am J Med. 2017;130(12):1415–1422.e4. doi:10.1016/j.amjmed.2017.06.028
   PubMed Web of Science ®Google Scholar
• Hunsche E, Chancellor JV, Bruce N. The burden of arthritis and nonsteroidal anti-inflammatory treatment. Pharmacoeconomics. 2001;19(1):1–15. doi:10.2165/00019053-200119001-00001
   Web of Science ®Google Scholar
• Yeomans ND, Graham DY, Husni ME, et al. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther. 2018;47(11):1453–1463. doi:10.1111/apt.14610
   PubMed Web of Science ®Google Scholar
• Obeid S, Libby P, Husni ME, et al. Cardiorenal risks of celecoxib, naproxen or ibuprofen in arthritis patients: a sub-anaylsis from the PRECISION Trial. Circulation. 2017;136(suppl_1):A20401–A20401.
   Google Scholar
• Fihn SD, Vaughan-Sarrazin M, Lowy E, et al. Declining mortality following acute myocardial infarction in the Department of Veterans Affairs Health Care System. BMC Cardiovasc Disord. 2009;9(1):44. doi:10.1186/1471-2261-9-44
   Web of Science ®Google Scholar
• Lakshminarayan K, Anderson DC, Jacobs DR, Barber CA, Luepker RV. Stroke rates: 1980–2000 the Minnesota Stroke Survey. Am J Epidemiol. 2009;169(9):kwp029. doi:10.1093/aje/kwp029
   Web of Science ®Google Scholar
• Parthan A, Leahy KJ, O’Sullivan AK, et al. Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome. Pharmacoeconomics. 2013;31(6):519–531. doi:10.1007/s40273-013-0054-5
   Web of Science ®Google Scholar
• Ara R, Pandor A, Stevens J, et al. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy? Eur J Prev Cardiol. 2012;19(3):474–483. doi:10.1177/1741826711406616
   Web of Science ®Google Scholar
• Fox K, Collier T, Wood D, et al. Contemporary mortality due to acute myocardial infarction, unstable angina and exertional angina in a population in South East London. J Assoc Physicians. 2006;99(7):437–443. doi:10.1093/qjmed/hcl064
   Google Scholar
• Weintraub WS, Boden WE. Reexamining the efficacy and value of percutaneous coronary intervention for patients with stable ischemic heart disease. JAMA Intern Med. 2016;176(8):1190–1194. doi:10.1001/jamainternmed.2016.3071
   Web of Science ®Google Scholar
• Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2014;28(6):575–585. doi:10.1007/s10557-014-6558-1
   PubMed Web of Science ®Google Scholar
• Kreisz FP, Merlin T, Moss J, Atherton J, Hiller JE, Gericke CA. The pre-test risk stratified cost-effectiveness of 64-slice computed tomography coronary angiography in the detection of significant obstructive coronary artery disease in patients otherwise referred to invasive coronary angiography. Heart Lung Circ. 2009;18(3):200–207. doi:10.1016/j.hlc.2008.10.013
   PubMed Web of Science ®Google Scholar
• Gattellari M, Goumas C, Biost FGM, Worthington JM. Relative survival after transient ischaemic attack: results from the Program of Research Informing Stroke Management (PRISM) study. Stroke. 2012;43(1):79–85. doi:10.1161/STROKEAHA.111.636233
   Web of Science ®Google Scholar
• Maetzel A, Krahn M, Naglie G The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis. 605 Third Ave, New York, NY 10158-0012 USA: Wiley-Liss Div John Wiley & Sons Inc; 2001:S310–S310.
   Google Scholar
• Retèl VP, Steuten LM, Foppen MHG, et al. Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation. BMC Cancer. 2018;18(1):895. doi:10.1186/s12885-018-4788-5
   Web of Science ®Google Scholar
• Luebke T, Brunkwall J. Cost-effectiveness of endovascular versus open repair of acute complicated type B aortic dissections. J Vasc Surg. 2014;59(5):1247–1255. doi:10.1016/j.jvs.2013.11.086
   Web of Science ®Google Scholar
• Hogan TJ, Elliott WJ, Seto AH, Bakris GL. Antihypertensive treatment with and without Benazepril in patients with chronic renal insufficiency. Pharmacoeconomics. 2002;20(1):37–47. doi:10.2165/00019053-200220010-00004
   Web of Science ®Google Scholar
• van Domburg RT, Hoeks SE, Welten GM, Chonchol M, Elhendy A, Poldermans D. Renal insufficiency and mortality in patients with known or suspected coronary artery disease. J Am Soc Nephrol. 2008;19(1):158–163. doi:10.1681/ASN.2006101112
   Web of Science ®Google Scholar
• Bae SC, Corzillius M, Kuntz KM, Liang MH. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. Rheumatology (Oxford). 2003;42(1):46–53. doi:10.1093/rheumatology/keg029
   Web of Science ®Google Scholar
• Brown JR, Rezaee ME, Marshall EJ, Matheny ME. Hospital mortality in the United States following acute kidney injury. Biomed Res Int. 2016;2016:1–6. doi:10.1155/2016/4278579
   Web of Science ®Google Scholar
• Neovius M, Jacobson SH, Eriksson JK, Elinder C-G, Hylander B. Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study. BMJ Open. 2014;4(2):e004251. doi:10.1136/bmjopen-2013-004251
   Web of Science ®Google Scholar